Status: Enrolling
Investigator: Eric Bernicker
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
This is an open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumours (non small cell lung cancer, renal cell carcinoma, bladder cancer or melanoma). Subjects will be treated ... Read more >
Status: Open Not Enrolling
Investigator: Eric Bernicker
Study Coordinator: Steven Hepp
Phone: 802.793.3352
To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab. ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Caroline Fitzgerald
Phone: 713.441.3250
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140, either alone or in combination with CDX-301, and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined. ... Read more >
Status: Open Not Enrolling
Investigator: Eric Bernicker
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), ... Read more >